Insider Selling: AtriCure (NASDAQ:ATRC) Insider Sells $233,280.00 in Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Vinayak Doraiswamy sold 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total transaction of $233,280.00. Following the sale, the insider directly owned 86,511 shares of the company’s stock, valued at approximately $3,363,547.68. The trade was a 6.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

AtriCure Price Performance

Shares of NASDAQ:ATRC traded down $0.74 during trading on Thursday, reaching $40.15. The stock had a trading volume of 906,805 shares, compared to its average volume of 800,251. The stock has a market capitalization of $2.04 billion, a PE ratio of 191.20 and a beta of 1.24. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.18. AtriCure, Inc. has a 52 week low of $25.36 and a 52 week high of $43.18. The business’s 50-day moving average price is $30.68 and its 200 day moving average price is $31.30.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The business had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same period in the prior year, the company earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities analysts predict that AtriCure, Inc. will post 0.2 earnings per share for the current year.

Analyst Ratings Changes

ATRC has been the subject of a number of research reports. Canaccord Genuity Group raised their target price on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Weiss Ratings upgraded shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research report on Tuesday. Raymond James Financial set a $52.00 target price on shares of AtriCure in a research note on Tuesday, July 21st. Finally, Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $48.50.

Institutional Investors Weigh In On AtriCure

Hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC raised its position in shares of AtriCure by 1.0% during the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock worth $2,700,000 after acquiring an additional 837 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in AtriCure by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock valued at $908,000 after acquiring an additional 1,230 shares during the last quarter. Goldman Sachs Group Inc. increased its position in AtriCure by 1.0% in the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after purchasing an additional 8,956 shares during the period. Jane Street Group LLC increased its position in AtriCure by 658.3% in the first quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock worth $3,254,000 after purchasing an additional 87,553 shares during the period. Finally, Strs Ohio bought a new stake in AtriCure during the 1st quarter worth about $158,000. 99.11% of the stock is owned by institutional investors and hedge funds.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.